PROGRAMME Venue: Crowne Plaza Hotel

Transcription

1 PROGRAMME Venue: Crowne Plaza Hotel

2 Obesitology Section of the Slovakian Diabetes Society Slovakian Diabetes Society in association with Biomedical Research Center Slovak Academy of Sciences organize 6 th Central European Congress on Obesity and 15 th Slovak Congress on Obesity 2017 October 5 th October 7 th, 2017 Crowne Plaza Hotel, Bratislava, Slovakia

3 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 3 Welcome Message Dear Colleagues, We are delighted to welcome you in the beautiful city of Bratislava in Slovakia at 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity CECON 2017 is being held in early October (5 th 7 th ), when we can expect nice, sunny beginning of autumn in Bratislava, which we sometimes call Indian summer. We are very excited to host this important conference in Bratislava. We hope to follow in the successful footsteps of the Central European region meetings in Karlovy Vary, Czech Republic (2008); Budapest, Hungary (2009, 2015); Olsztyn, Poland (2011) and Cluj-Napoca, Romania (2013). In 2017, CECON will offer excellent science and networking opportunities for all the colleagues from Central Europe and beyond. The International Scientific and Local Organizing Committees and the Boards of Obesitology Section of the Slovakian Diabetes Society have strived to create excellent scientific programme, integrating state-of-the-art research and current treatment modalities, including lifestyle interventions, metabolic surgery and pharmacotherapy. Meeting will provide maximum opportunity for interaction between delegates, experts and re searchers to present their findings and to develop collaborations, hopefully leading to new knowledge helpful to the patients. The program was designed to provide diversity of insights for clinicians, health care practitioners, nutritionists, surgeons, psychologists, physical activity professionals, nurses, pharmacists and researchers. We have created an attractive and diverse scientific programme but discussions could surely continue while enjoying coffee & vitamin breaks, lunches and receptions. You should not miss the opportunity to cruise the beautiful Danube river and to enjoy the dinner at the Bratislava Castle Restaurant with an amazing view. Bratislava and its surroundings provide amazing places to visit, majestic churches, charming burgher houses and elegant palaces, tiny squares, romantic little streets, and towering over all this, the stately Castle, visible from afar. You can find everything here, on a small-scale and easily accessible. We welcome you to Bratislava and to the 6 th CECON and 15 th Slovak Congress on Obesity! With kind regards Ľubomíra Fábryová President of 6 th CECON and 15 th Slovak Congress on Obesity President Obesitology Section of the Slovakian Diabetes Society Pavol Holéczy Vice President of 6 th CECON and 15 th Slovak Congress on Obesity President of the working group Bariatric/Metabolic Surgery Obesitology Section of the Slovakian Diabetes Society Jozef Ukropec Chair of scientific committee of 6 th CECON and 15 th Slovak Congress on Obesity Member of the Physical Activity working group Obesitology Section of the Slovakian Diabetes Society

4 4 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 Auspices The patronage over the 6 th Central European Congress on Obesity and 15 th Slovak Congress on Obesity took Mr. Andrej Kiska President of the Slovak Republic

5 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 5 Dean of the Faculty of Medicine Comenius University in Bratislava Juraj Šteňo and Minister of Health of the Slovak Republic Tomáš Drucker President of the European Association for the Study of Obesity Hermann Toplak Vice-President Middle Region of the European Association for the Study of Obesity Dana Müllerová President of the Slovakian Diabetes Society Emil Martinka

6 6 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 Awards Honorary membership ot the Obesitology Section Slovakian Diabetes Society Hermann Toplak Professor Hermann Toplak graduating with a M.D. from the University of Graz in 1984, then he went into military training with aeromedicine before becoming a resident in Laboratory Medicine, at the Metabolism Unit of the Department of Pediatrics at the University of Graz. He then was a resident in Surgery and Internal Medicine in the General Hospital of Rottenmann, Austria as well as a Resident at the Metabolism Unit of the Department of Pediatrics at the University of Berne, Switzerland. Since 1988 he is working in the department of Medicine at the Karl-Franzens-University, Graz, where in 1990 he became the Head of the Metabolism Unit. Since October 1997 he is also a Specialist for Endocrinology and Metabolism and Associate Professor of Medicine. Dr. Toplak is in charge of the entire Medical Curriculum in Internal medicine at the Medical University Graz and holds a full professorship for continuing professional development (CPD) and life long learning. He is a member of various national and international associations such as the Austrian Obesity Association, where he was President from and , and the Austrian Diabetic Association, where he is a Council Member since 2005 and the President from Since 2001 he is the Austrian representative in the General Council of IASO where he is also involved in the Education Management Task Force and from 2005 was Regional Vice President for Middle Europe and then from 2009 he was the Secretary of EASO, from 2012 he was President-Elect and since 2015 he is President of EASO, he also has been a long standing and member of the Obesity Management Task Force (OMTF) and running a EASO-COM. Dana Műllerová Dana Mullerova, M.D., Ph.D., is Head of the Department of Public Health and Preventive Medicine and Vice Dean for Faculty Development at the Charles University in Prague, Faculty of Medicine in Pilsen. Educated at Charles University, she is specialised in internal medicine, her research interests comprise the prevention and treatment of NCD, especially obesity, and its relation to nutrition and obesogens. Dr. Mullerova is an Assoc. Prof in both: Department of Public Health and Preventive Medicine and Department of Internal Medicine I, the Division of Clinical Nutrition, the Obesity Treatment Centre at Faculty hospital in Pilsen. She works in European Platform on Diet, Physical activity and Health, during period 2014 to 2015 as a representative of EASO, currently as a Czech Republic MS representative. She is a member of Prevention and Public Health Task Force of EASO and she has served on committees in Czech Republic that have formulated recommendation or guidelines on obesity prevention and treatment. She as a senior with her colleagues developed the Czech National Action plan on Healthy Diet and Obesity Prevention for , under National Strategy Health Currently she is Vice-president Middle Region of EASO and a past Vice-president of the Czech Association for the Study of Obesity. Vojtěch Hainer Career of Vojtech Hainer was associated with the Departments of Medicine at The First Faculty of Medicine, Charles University in Prague over more than thirty years. He focused his interest mainly on endocrinology and obesity. In 1988 he founded the first Obesity Unit in former Czechoslovakia. During the period , he acted as a director of the Institute of Endocrinology in Prague. In 1993, he co-founded the Czech Society for the Study of Obesity, of which he was the first president. His extensive international responsibilities included the Obesity Management Task Force of the European Association for the Study of Obesity /EASO/ (2001 ongoing, chairman ) and the Executive Committee of the European Association for the Study of Obesity ( , president: ). He has been a member of the Editorial Boards of several medical journals. He participated in organizing the European Congresses on Obesity /ECO/ (member of international scientific committees, co-president of the 13 th ECO in 2004), the Congresses on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), Central European

7 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 7 Congresses on Obesity (CECON) and the Round Table Meetings on Obesity Management. He was an author of several textbooks on obesity and co-author of the Guidelines on Obesity Management in Europe. He has published over 200 papers in medical journals, 145 of them appeared on PubMed. His research topics included: very low energy diets, factors affecting outcomes of obesity treatment, genetic and environmental aspects of weight change in obesity, eating behavior and health risks, pathogenesis and health risks of obesity in adolescence, evaluation of anti-obesity drugs, adenovirus infection and obesity, hormonal and metabolic response to bariatric surgery. Bronze medal of the Slovakian Diabetes Society Ľubomíra Fábryová Ľubomíra Fábryová, MD, PhD., has graduated from Medical Faculty of Comenius University in Bratislava (Slovakia) and completed residency training in 4th Dept. of Internal Medicine Comenius University (internal medicine and diabetology, metabolic disorders and nutrition). In 2008 she received PhD in Internal Medicine from Medical Faculty of Comenius University. At present time she is a head of a metabolic center MetabolKLINIK in Bratislava, Department for Diabetology and Metabolic Diseases (focused on management of diabetic patients, overweight and obese patients and high risk patients with familiar hypercholesterolaemia). Rich is also the publishing and editorial activities, as well as work in the editorial boards of journals. She has published more than 200 papers in domestic and foreign medical journals. She is the author of chapters in the monograph General endocrinology, editor and author of chapters in the monograph Clinical Obesitology and many others. She has served as national, principal coordinator and scientific guarant of slovakian research projects and studies (WHO MED PED project, Screening of serious dyslipidaemias in quadragerian Slovak population (2003, 2006), AtheroEduc project (2009, 2010), Atherogenic dyslipidemia II in Diabetes Mellitus II survey in Slovak Republic (2011, 2012), ObezitaEDUC project ( ) and as a national coordinator and principal investigator on a number of multicenter clinical studies. Dr. Fábryová is teaching at Dept. for diabetology, metabolic disorders and nutrition of Slovak Medical University and Medical Faculty Comenius University in Bratislava, she is member of PhD Study Board in the field of internal medicine at Medical Faculty of Comenius University in Bratislava. She has lectured on metabolic disorders topics (diabetes, hyperlipoproteinaemias and obesity). Dr. Fábryová is a member of the Executive Committee of Slovakian Diabetes Society, scientific secretary and since 2014 president of the Obesity section Slovakian Diabetes Society. For many years she has been active in the Slovak Association of Atherosclerosis (scientific secretary, president, past president). She is a founder of a School Lipidolo gy. She is a member of many national and international societes (Slovak Medical Society, Slovak Cardiology Society, EASD, EAS, IAS, EASO, WOF) and works as a member of an international organization R3i (Residual Risk Reduction Initiative). Sečanský Award Imrich Sečanský (September 6 th, 1914 Budapest October 29 th, 2013 Bratislava) After his studies at the Medical Faculty at Charles University in Prague and at the Slovak University in Bratislava he began to work as a physician at the Sanatorium of the Workers Social Insurance Company in Slovakia. During the post-war period, he understood that nutrition is important part of the therapy. He therefore established a nutritional system in hospitals driven by the principle that energy content and specific food components should be indicated specifically according to the patient`s needs (disease character and stage). Moreover, he stands behind the canteen alimentation system for schools, factories and public sector in the post-war Slovakia. Imrich Sečanský was the founder and the director of the State Institute for the Nutrition of People & Dietetics, the founder of a School for Dietary Nursing, the co-founder of the very first Hotel School in Piešťany and the first dietary restaurant in Czechoslovakia. From 1953 to 1994 he worked as an internal medicine specialist

8 8 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 and diabetologist at the National Health Institute in Bratislava. He actively worked as a physician until he was 82 years old. His research and publishing activities in the field of internal medicine, diabetology, dietetics and nutrition were rich and abundant. He focused on these issues in more than 20 monographic and collective writings, several of which were translated into Czech, Polish and Russian. His popular articles have been published since 1930 in major Slovak newspapers (Práca, Pravda, Smena, Večerník) and magazines (DAV, Pero, Slovenka, Slovensko, Život). He is also the author of smemoir literature, Spomienky a vyznania lekára. Polstoročie slovenskej internej medicíny, for which he was awarded the Egon Erwin Kisch prize (1998). He received many awards for his scientific and publishing activities. In 2013, he was inducted to the Slovak Medical Society Hall of Fame. Obesitology Section of the Slovakian Diabetes Society is awarding the Dr. Imrich Sečanský Award on the occasion of the Slovak Obesitology Congress for an invaluable contribution to the field of obesitology at both national and international level. The first holder of the Sečanský Award A/prof Boris Krahulec, M.D., PhD. was the first chairman of the Obesitology Section of the Slovak Diabetology Society ( ) and the founder of Slovak Obesitology Congress. In 2016, the Sečanský Award was presented to A/prof. Igo Kajaba, MD, PhD., a specialist in nutrition, internal medicine, gastroenterology and clinical dietology. This year Sečanský Award is to be presented to the professor Iwar Klimeš, MD., DSc.., for his life-time scientific achievements in the field of clinical and molecular pathophysiology and genetics of obesity, metabolic and endocrine diseases. Iwar Klimeš Professor Iwar Klimeš, professor of pathophysiology, endocrinology, diabetes and metabolism at the Comenius University School of Medicine in Bratislava has spent four decades in basic and clinical research in integrated physiology, genetics, diagnostics and treatment of diabetes, metabolic and endocrine diseases. He worked at the Slovak Academy of Sciences, where he served as a director of the Institute of Experimental Endocrinology (currently part of the Biomedical Research Center) from 2008 until During his research career he worked at several excellent scientific institutions all over the world including NIDDKD-NIH, Phoenix, Arizona, USA; Department of Medicine, Stanford University, Palo Alto, CA, USA; Medlantic Research Institute, Washington, DC, USA; University of Leicester, UK and Garvan Research Institute, Sydney, Australia. Professor Klimeš established the Laboratory of Diabetes and Metabolic Disorders at Slovak Academy of Sciences and DIABGENE, the first DNA diagnostic laboratory for monogenic diabetes and obesity in Slovakia. His professional interests reached for many pathophysiological components leading to type 2 diabetes mellitus, such as obesity, impaired lipid metabolism and insulin resistance and included molecular mechanisms and important clinical aspects of the aforementioned pathophysiologies. In the last decade professor Klimeš has focused on the causal mechanisms explaining the various monogenic forms of diabetes mellitus and severe syndromic obesity. His main research achievements include the first pathophysiological explanation of intensified insulin treatment in patients with type 2. diabetes, his laboratory also participated to the breakthrough international study providing a proof of concept for the possibility of life-changing pharmacological treatment in patients with specific form of monogenic diabetes associated with defect in insulin secretion due to specific mutations in potassium channel of the B-cells of the pancreatic islets. In Slovakia, he created new research school aimed at elucidating the role of genetics and diet in the pathophysiology of diabetes and metabolic disorders. Professor Klimeš was the editor of several international journals including Diabetologia, Archives of Biochemistry and Physiology and Diabetes and Stoffwechsel. He served as international panel expert evaluator for European Commission. Moreover, he served as president of the Slovak Endocrine Society, chairmen of the Slovak Research Professor Board and vice-president of the Slovakian Diabetes Society. His scientific work led to more than 200 in extenso publications, he is author or co-author of 6 monographs, the editor of 4 textbooks on diabetes, endocrinology and obesity, and he was invited as a plenary speaker to more than 20 international scientific meetings.

9 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 9 Congress Committee Ľubomíra Fábryová President of the 6 th CECON and 15 th Slovak Congress on Obesity President of the Obesitology Section of Slovakian Diabetes Society Pavol Holéczy Vice President of the 6 th CECON and 15th Slovak Congress on Obesity President of the working group Bariatric/Metabolic Surgery Obesitology Section of Slovakian Diabetes Society Jozef Ukropec Chair of Scientific Committee of the 6 th CECON and 15 th Slovak Congress on Obesity Member of the Physical Activity working group Obesitology Section of the Slovakian Diabetes Society International Scientific Committee Martin Fried, Czech Republic Vojtech Hainer, Czech Republic Eszter Halmy, Hungary Martin Haluzik, Czech Republic Svetoslav Handjiev, Bulgaria Teodora Handjieva-Darlenska, Bulgaria Michael Holecki, Poland Marie Kunešová, Czech Republic Dana Müllerová, Czech Republic Magdalena Olszanecka-Glinianowicz, Poland Šárka Slabá, Czech Republic Constantine Tsigos, Greece Herman Toplak, Austria Mariusz Wylezol, Poland Volkan Yumuk, Turkey National Scientific and Organizing Committee (Slovakia) Daniela Gašperíková Viera Kissová Boris Krahulec Imrich Mucska Emil Martinka Ľubomír Skladaný Barbara Ukropcová Vladimír Uličiansky

10 10 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 Congress Organizers Obesitology Section of the Slovakian Diabetes Society Slovakian Diabetes Society Biomedical Research Center Slovak Academy of Sciences About Obesitology Section of the Slovakian Diabetes Society Obesitology Section of Slovakian Diabetes Society (OS SDS) was founded in 2002 with the aim to promote research and dissemination of knowledge in the field of obesity and related aspects relevant to society and scientific community (epidemiology, nutrition, physical activity, management including behaviour and comorbidities). The main task of the OS SDS is to bring together physicians, healthcare professionals and scientists involved in obesity and to represent their professional interests with the ultimate goal to generate new knowledge and to support innovative treatment strategies for patients with obesity and comorbidities ( Currently OS SDS has 157 active members. OS SDS presents, publishes and promotes practical guidelines, suggestions and expert-opinions arising from the clinical and basic obesitology science, bringing in the cutting-edge diagnostic, therapeutic and scientific practices, discussing ethical issues, legal norms and further education in the field of obesitology. OS SDS organizes scientific meetings and encourages the participation of its members at scientific meetings at home and abroad (EASO, CECON, World Obesity Federation meetings). OS SDS informs its members about the latest diagnostic and therapeutic procedures, collaborates with scientific and health organizations both in Slovakia and abroad and supports collaborative efforts and international exchange of experts. OS SDS supports research in obesitology and proposes awards to SDS for achievements in the field of obesitology. Since its foundation in 2002 OS SDS organizes annual Slovak Congress on Obesity with international participation, since 2015 separate blocks of lectures for nurses and nutrition assistants were introduced. In 2018, block of lectures dedicated to patients organizations and support will be launched for the first time. In 2009, OS SDS coordinated publication of The Guidelines for the obesity management in adults and contributed to The Interdisciplinary European Guidelines for Metabolic Surgery. 42 renowned experts contributed to monography entitled Clinical Obesitology (2013) the first handbook on Obesity published in Slovakia. Members of OS-SDS actively contribute to Obesity EDUC program presenting major issues of Obesity management and research to medical professional community on the pages of Via Practica (the journal for General Practitioners). State-of-the-art obesitology knowledge dissemination is also provided in collaboration with professional journals Forum Diabetologicum and Bedeker Zdravia as well as with the e-learning portal enabling an access to state-of-the-art educational presentations for physicians. OS SDS is an active member of Slovak Medical Society and Slovak Diabetes Society. Members of OS SDS actively participated in creating the scientific program of 5 th CECON 2015 in Budapest. Slovakian Diabetes Society and Obesitology Section of Slovakian Diabetes Society ratified and endorsed the DSS-II consensus statements and guidelines at April 10 th OS SDS have prepared various activities contributing to the European Obesity Day by establishing 1 st and 2 nd Slovak Obesity Day (2016, 2017) was organized in several cities in Slovakia. The 3 rd European and Slovak Obesity Day is scheduled for May 19 th, Today we are very proud to welcome you on 6 th Central European Congress on Obesity and 15 th Slovak Congress on Obesity in Bratislava.

11 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 11 Congress Secretariat GUARANT International spol. s r.o. Na Pankráci Prague 4 Czech Republic Phone: cecon2017.secretariat@guarant.cz Website: Floor Plan

12 12 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 Exhibition EXHIBITION HOURS Thursday, October 5 th 13:00 19:30 Friday, October 6 th 08:00 19:00 Saturday, October 7 th 08:30 17:00 EXHIBITION DISMANTLE Saturday, October 7 th 18:15 19:00 The organizers would like to express their thanks to the following partners for their support: BRONZE PARTNER SYMPOSIUM PARTNER AstraZeneca INDUSTRY SPONSORED PRESENTATION Eli Lilly & Company INFORMATION SYSTEM PARTNER Amgen PARTNERS EXHIBITORS TEVA Pharmaceuticals Slovakia s.r.o. Amgen Slovakia s.r.o. Sanofi-aventis Pharma Slovakia s.r.o. Novartis s.r.o. Wörwag Pharma GmbH & Co. KG seca gmbh & co. Kg NutriFood s.r.o.

13 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 13 MEDIA PARTNERS Solen, s.r.o. Lekárske Listy, Publisher MAFRA Slovakia, a.s. Interná Medicína, Publisher A-medi management, s.r.o. Bedeker Zdravia, Publisher RE-PUBLIC s.r.o. Facta Medica, s.r.o. Remedia, Publisher MEDICAL TRIBUNE CZ, s.r.o. PARTNERS VITAMIN BREAK

14

15 1. polypill: atorvastatín / perindopril arginín / amlodipín n= molekuly s najlepšou EBM Razantné zníženie TK a LDL cholesterolu 1,2 Vyznamnejšia redukcia rizika KV príhod 3 Lepšia adherencia 4 Lipertance 20 mg/5 mg/5 mg, Lipertance 20 mg/10 mg/5 mg, Lipertance 40 mg/10 mg/10 mg, filmom obalené tablety ZLOŽENIE*: Lipertance 20 mg/5 mg/5 mg, 20 mg/10 mg/5 mg, 40 mg/10 mg/10 mg filmom obalené tablety obsahujú 20 mg atorvastatínu (ator)/ 5 mg perindoprilarginínu (per)/ 5 mg amlodipínu (amlo), 20 mg ator/10 mg per/5 mg amlo, 40 mg ator/10 mg per/10 mg amlo. Obsahuje laktózu ako pomocnú látku. INDIKÁCIE*: Substitučná liečba esenciálnej hypertenzie a/alebo stabilnej ischemickej choroby srdca v spojení s primárnou hypercholesterolémiou alebo kombinovanou hyperlipidémiou u dospelých pacientov primerane kontrolovaných s atorvastatínom, perindoprilom a amlodipínom podávaných súbežne v rovnakých dávkach ako vo fixnej kombinácii. DÁVKOVANIE A SPÔSOB PODÁVANIA*: Jedna tableta jedenkrát denne ráno pred jedlom. Lipertance nie je vhodný na začiatočnú liečbu. Ak sa vyžaduje zmena dávkovania, titrácia sa má vykonať s jednotlivými zložkami. Starší pacienti a pacienti so zlyhaním obličiek: časté monitorovanie kreatinínu a draslíka. Klírens kreatinínu (Clcr) < 60 ml/min: nevhodné. Porucha funkcie pečene: môže sa používať s opatrnosťou. Lipertance je kontraindikovaný u pacientov s aktívnym ochorením pečene. Pediatrická populácia: nemá sa používať. KONTRAINDIKÁCIE*: Precitlivenosť na liečivo alebo na ktorýkoľvek iný inhibítor ACE, alebo deriváty dihydropyridínu, alebo statín, alebo na ktorúkoľvek z pomocných látok, aktívne ochorenie pečene alebo neobjasnené pretrvávajúce zvýšenia sérových transamináz prekračujúce 3-násobok hornej hranice normálu, počas gravidity, počas dojčenia a u žien v reprodukčnom veku, ktoré nepoužívajú vhodné antikoncepčné opatrenia (pozri časť GRAVIDITA* a LAKTÁCIA*), ťažká hypotenzia, šok (vrátane kardiogénneho šoku), obštrukcia prietoku ľavej komory (napr. hypertrofická obštrukčná kardiomyopatia a vysoký stupeň aortálnej stenózy), hemodynamicky nestabilné srdcové zlyhávanie po akútnom infarkte myokardu, anamnéza angioedému (Quinckeho edém) súvisiaceho s predchádzajúcou liečbou inhibítorom ACE, hereditárny alebo idiopatický angioedém, súbežné použitie s liekmi obsahujúcimi aliskiren u pacientov s diabetom mellitus alebo poruchou funkcie obličiek (GFR < 60 ml/min/1,73 m 2 ) (pozri časť INTERAKCIE*). UPOZORNENIA*: Osobitné upozornenia a opatrenia pre používanie: Vplyv na pečeň: testy funkcie pečene sa majú vykonávať pravidelne a v prípade zvýšenia hladín transamináz sa majú pacienti monitorovať až do odstránenia tohto zvýšenia. Zastaviť liečbu, ak sa vyskytne žltačka alebo výrazné zvýšenie hepatálnych enzýmov (sérové transaminázy prekračujúce 3-násobok hornej hladiny normálu (ULN)) a u pacientov s aktívnym ochorením pečene. Používať s opatrnosťou u pacientov s poškodením funkcie pečene, ktorí konzumujú alkohol a/alebo majú ochorenie pečene v anamnéze. Vplyv na kostrový sval: zastaviť liečbu, ak zvýšenie hladín kreatínkinázy (CK) > 10 x ULN alebo ak sa objavia svalové symptómy so zvýšením CK hladín > 5 x ULN alebo pri podozrení na rabdomyolýzu. S opatrnosťou je potrebné postupovať, keď sa Lipertance používa s niektorými liekmi, ktoré môžu zvýšiť plazmatickú koncentráciu atorvastatínu, a tým riziko rabdomyolýzy, ako sú silné inhibítory CYP3A4 alebo transportné proteíny (napr. cyklosporín, ketokonazol, ritonavir...). Intersticiálne ochorenie pľúc: ak je podozrenie, liečba sa má prerušiť. Diabetes mellitus: U diabetických pacientov sa má kontrola glykémie starostlivo monitorovať počas prvého mesiaca liečby. Srdcové zlyhávanie: používať s opatrnosťou. Hypotenzia: monitorovať krvný tlak, renálnu funkciu a draslík u pacientov s vysokým rizikom symptomatickej hypotenzie (hypovolémia alebo závažná renín-dependentná hypertenzia) alebo so symptomatickým srdcovým zlyhávaním (s alebo bez renálnej nedostatočnosti), alebo s ischemickou chorobou srdca alebo cerebrovaskulárnym ochorením. Prechodná hypotenzná odpoveď nie je kontraindikáciou na podávanie ďalších dávok, ktoré je možné podať zvyčajne bez ťažkostí, keď sa krvný tlak zvýši po zväčšení objemu. Stenóza aortálnej a mitrálnej chlopne/ hypertrofická kardiomyopatia: používať s opatrnosťou a pozri časť KONTRAINDIKÁCIE*. Transplantácia obličky: nie sú skúsenosti po nedávnej transplantácii. Porucha funkcie obličiek: monitorovať draslík a kreatinín; individuálna titrácia dávky s jednotlivými zložkami sa odporúča ak Clcr < 60 ml/min. U pacientov so stenózou renálnej artérie môže byť zvýšená hladina urey v krvi a kreatinínu; s renovaskulárnou hypertenziou, riziko ťažkej hypotenzie a renálnej insuficiencie. Amlodipín sa môže používať v normálnych dávkach u pacientov so zlyhaním obličiek. Amlodipín nie je dialyzovateľný. Hemodyalizovaní pacienti: používať s opatrnosťou. Precitlivenosť/Angioedém: zastaviť liečbu a monitorovať až do úplného vymiznutia symptómov. Angioedém spojený s edémom hrtana môže byť fatálny. Súbežné použitie inhibítorov mtor: zvýšené riziko angioedému**. Anafylaktoidné reakcie počas aferézy lipoproteínov s nízkou hustotou (LDL): zriedkavo, pacienti zaznamenali život ohrozujúce anafylaktoidné reakcie, dočasne ukončiť liečbu pred aferézou. Anafylaktoidné reakcie počas desenzibilizácie: dočasne ukončiť podávanie pred liečbou. Tieto reakcie sa po náhodnej opätovnej expozícii objavili znova. Neutropénia/Agranulocytóza/Trombocytopénia/Anémia: používať s najvyššou opatrnosťou u pacientov s kolagénovým vaskulárnym ochorením, imunosupresívnou liečbou, liečbou s alopurinolom alebo prokaínamidom, odporúča sa pravidelne monitorovať počet leukocytov. Rasa: perindopril môže byť menej účinný a spôsobuje vyššie percento angioedému u pacientov čiernej rasy ako u pacientov iných rás. Kašeľ: ustupuje po ukončení liečby. Operácia/anestézia: zastaviť liečbu jeden deň pred operáciou. Hyperkaliémia: časté monitorovanie draslíka v krvi v prípade renálnej insuficiencie, zhoršenia renálnej funkcie, vek (> 70 rokov), diabetes mellitus, dehydratácie, akútnej srdcovej dekompenzácie, metabolickej acidózy a súbežného používania draslík šetriacich diuretík a doplnkov draslíka alebo soľných náhrad s obsahom draslíka. Kombinácia s lítiom: neodporúča sa. Duálna inhibícia systému renín-angiotenzín-aldosterón (RAAS): súbežné použitie inhibítorov ACE, blokátorov receptorov angiotenzínu II alebo aliskirenu zvyšuje riziko hypotenzie, hyperkaliémie a zníženej funkcie obličiek (vrátane akútneho zlyhania obličiek). Duálna inhibícia RAAS sa preto neodporúča. Inhibítory ACE a blokátory receptorov angiotenzínu II sa nemajú súbežne používať u pacientov s diabetickou nefropatiou. Galaktózová intolerancia/glukózo-galaktózová malabsorpcia/lapónsky deficit laktázy: nemá sa užívať. INTERAKCIE*: Kontraindikované: aliskiren (u pacientov s diabetom mellitus alebo poruchou funkcie obličiek). Neodporúča sa: silné inhibítory CYP3A4, aliskiren, súčasná liečba s inhibítormi ACE a blokátorom receptora angiotenzínu, estramustín, lítium, draslík šetriace diuretiká (napr. triamterén, amilorid, eplerenón, spironolaktón), soli draslíka, dantrolén (infúzia), grapefruit alebo grapefruitový džús. S opatrnosťou: induktory CYP3A4, digoxín, ezetimib, kyselina fusidová, gemfibrozil/deriváty kyseliny fibrovej, inhibítory transportných proteínov, warfarín, antidiabetiká (inzulíny, perorálne antidiabetiká), baklofén, nesteroidné protizápalové lieky (NSAID) (vrátane aspirínu 3 g/deň), racekadotril, inhibítory mtor (napr. sirolimus, everolimus, temsirolimus)**, kolchicín, kolestipol, perorálna antikoncepcia, gliptíny (linagliptín, saxagliptín, sitagliptín, vildagliptín), sympatomimetiká, tricyklické antidepresíva/antipsychotiká/anestetiká, zlato, digoxín, atorvastatín, warfarín alebo cyklosporín, takrolimus, antihypertenzíva a vazodilatanciá. GRAVIDITA A LAKTÁCIA*: Lipertance je kontraindikovaný počas gravidity a laktácie. FERTILITA*: Reverzibilné biochemické zmeny spermií u niektorých pacientov liečených blokátormi kalciového kanálu. OVPLYVNENIE SCHOPNOSTI VIESŤ VOZIDLÁ A OBSLUHOVAŤ STROJE*: Schopnosť viesť vozidlá a obsluhovať stroje môže byť znížená v prípade závratu, bolesti hlavy, únavy, slabosti a nauzei. Opatrnosť sa odporúča najmä na začiatku liečby. NEŽIADUCE ÚČINKY*: Veľmi časté: edém. Časté: nazofaringitída, hypersenzitivita, hyperglykémia, somnolencia, závrat, bolesť hlavy, dysgeúzia, parestézia, vertigo, porucha zraku, diplopia, tinnitus, palpitácie, hypotenzia (a účinky súvisiace s hypotenziou), sčervenanie, faryngolaryngeálna bolesť, epistaxa, kašeľ, dyspnoe, nauzea, vracanie, bolesť v hornej a dolnej časti brucha, dyspepsia, hnačka, zápcha, zmenená činnosť čriev, flatulencia, vyrážka, pruritus, opuch kĺbov, opuch členka, bolesť v končatine, artralgia, svalové spazmy, myalgia, bolesť chrbta, asténia, únava, abnormálne hodnoty pečeňových testov, zvýšená hladina kreatínkinázy v krvi. Menej časté: rinitída, eozinofília, hypoglykémia, hyponatriémia, hyperkaliémia reverzibilná po ukončení liečby, anorexia, insomnia, zmenená nálada (vrátane úzkosti), porucha spánku, depresia, nočné mory, tremor, synkopa, hypestézia, amnézia, arytmia (vrátane bradykardie, ventrikulárnej tachykardie a atriálnej fibrilácie), rozmazané videnie, tachykardia, vaskulitída, bronchospazmus, sucho v ústach, pankreatitída, eruktácia, hepatitída buď cytolytická alebo cholestatická, urtikária, purpura, zmeny sfarbenia pokožky, hyperhidróza, exantém, alopécia, angioedém, pemfigoid, fotosenzitívne reakcie, bolesť krku, svalová únava, porucha močenia, noktúria, polakiúria, zlyhanie obličiek, erektilná dysfunkcia, gynekomastia, bolesť na hrudi, bolesť, malátnosť, periférny edém, pyrexia, zvýšená hladina urey v krvi, zvýšená hladina kreatinínu v krvi, zvýšenie telesnej hmotnosti, pozitívny nález bielych krviniek v moči, zníženie telesnej hmotnosti, pád. Zriedkavé: trombocytopénia, stav zmätenosti, periférna neuropatia, cholestáza, zhoršenie psoriázy**, Stevensov-Johnsonov syndróm, toxická epidermálna nekrolýza, multiformný erytém, myopatia, myozitída, rabdomyolýza, tendinopatia, niekedy komplikovaná ruptúrou, zvýšenie pečeňových enzýmov, zvýšená hladina bilirubínu v krvi. Veľmi zriedkavé: leukopénia/neutropénia, agranulocytóza alebo pancytopénia, hemolytická anémia u pacientov s vrodenou deficienciou G-6PDH, znížený hemoglobín a znížený hematokrit, anafylaxia, zvýšený svalový tonus, strata sluchu, infarkt myokardu pravdepodobne sekundárny v dôsledku nadmernej hypotenzie u vysokorizikových pacientov, angína pektoris, cievna mozgová príhoda, pravdepodobne sekundárna v dôsledku nadmernej hypotenzie u vysokorizikových pacientov, eozinofilná pneumónia, gastritída, gingiválna hyperplázia, žltačka, zlyhanie pečene, exfoliatívna dermatitída, akútne zlyhanie obličiek. Neznáme: imunitne sprostredkovaná nekrotizujúca myopatia, extrapyramidálna porucha (extrapyramidálny syndróm). PREDÁVKOVANIE*. VLASTNOSTI*: Atorvastatín je selektívny, kompetitívny inhibítor HMG-CoA reduktázy. Perindopril je inhibítor enzýmu, ktorý konvertuje angiotenzín I na angiotenzín II (angiotenzín-konvertujúci enzým, ACE). Amlodipín je inhibítor vstupu kalciových iónov z dihydropyridínovej skupiny (blokátor pomalého kanála alebo antagonista kalciových iónov) a inhibuje transmembránový vstup kalciových iónov do hladkých svalov srdca a ciev. BALENIE*: 30 alebo 90 (3 balenia po 30) filmom obalených tabliet lieku Lipertance 20mg/5mg/5mg, 20mg/10mg/5mg, 40mg/10mg/10mg. DÁTUM REVÍZIE TEXTU: 05/2017 Držiteľ rozhodnutia o registrácii: Les Laboratoires Servier, 50 rue Carnot, Suresnes cedex, Francúzsko * Podrobné informácie sú uvedené v Súhrne charakteristických vlastností lieku, ktorý vám poskytneme na adrese: Servier Slovensko, spol. s r. o., Pribinova 10, Bratislava, tel.: 02/ , fax: 02/ **Všimnite si, prosím, zmenu v informácii o lieku Literatúra: 1. C. Vlachopoulos. et al., Effectiveness of perindopril/amlodipine fxed dose combination in everyday clinical practice: results from the EMERALD study, Current Medical Research and Opinion, 2016; 32:9, Law MR et al. BMJ. 2003;326: Bertrand M et al. Cardiovasc Drugs Ther.August 2016, Volume 16, Issue 4, pp Huffman MD. PLOS Med. 2015;12(8):e LIP IS Servier Slovensko, spol. s r. o., Pribinova 10, Bratislava, tel.: , fax:

16 16 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 General Information CONGRESS VENUE Crowne Plaza Bratislava Hodžovo nám Bratislava Slovakia REGISTRATION On-Site Registration Fees EASO Member Fee Non-EASO Member Fee Student Fee 229 EUR 259 EUR 179 EUR Registration fees include 20 % VAT. The Registration Fee Includes: Admittance to all scientific sessions, poster and exhibition area Congress Kit Opening Hours Thursday, October 5 th 11:30 18:00 Friday, October 6 th 7:30 19:00 Saturday, October 7 th 7:30 16:00 TOURS Tour4U, s.r.o. Šikmá 4, Bratislava info@tour4u.sk Telephone: The tours can be booked via or phone. INSTRUCTIONS FOR SPEAKERS Please submit all digital files needed for your presentation in congress room London I+II. Our technician will help you upload all files so everything is ready before the session. To check your presentation please come to the congress room at least 1,5 hour before the beginning of your session (during the coffee or lunch break). In case your speech has been scheduled for a morning session, please come to check your presentation the day before your presentation. During your lecture, you will be using the Remote Control to facilitate the progress of your presentation. All speakers are kindly requested to keep to the allocated time for their presentation. All presentation will be deleted from all the PC used during the congress. ABSTRACT BOOK Abstract book in digital format can be downloaded from: Password: C3CON2017

17 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 17 INSTRUCTIONS FOR E-POSTER PRESENTATIONS Three e-poster veiwing stations will be visibly located in the room London III (2 stations) and in hotel foyer (1 station). E-posters will be displayed throughout the Congress and available for all participants. Moderated (Oral) E-poster presentations Moderated (Oral) E-poster presentations will be granted 3 minutes to present the study, followed by 1 minute for Q&A or discussion. Moderated E-posters will be presented on Saturday, October 7 th 2017 during the Guided poster session (12:45 13:45), presenting authors are requested to attend the poster session. Unmoderated (Displayed) E-poster presentations Unmoderated (Displayed) E-posters are presented as non-discussion posters only, and will be exhibited digitally for the duration of the congress. The posters will be available for viewing by all delegates at the digital poster stations. BADGES Participants will receive a name badge upon registration. Everyone is kindly requested to wear the name badge when atttending the Congress. Only participants who are wearing their name badge will be admitted to the lecture rooms. Name badges are color-coded as follows: PARTICIPANT blue FACULTY red EXHIBITOR green ORGANIZER orange WI-FI CONNECTION Free wi-fi connection is at disposal in all the Congress meeting rooms and foyer area. Network: CrownePlaza No password is required. EACCME ACCREDITATION The 6 th Central European Congress on Obesity & 15 th Slovak Congress on Obesity is accredited by the European Accreditaion Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European union of Medical Specialist (UEMS), The 6th Central European Congress on Obesity & 15th Slovak Congress on Obesity has been granted 18 European CME credits (EACCME s) by the European Accreditation Council for Continuing Medical Education (EACCME ). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the proces to convert EACCME credit to AMA credit can be found at internationalcme. Live educational activites, occruriing outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. MEDTECH EUROPE The 6 th Central European Congress on Obesity (CECON) & 15 th Slovak Congress on Obesity 2017 is COMPLIANT with the MedTech Europe Code of Ethical Business Practice.

18 18 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 CERTIFICATE OF ATTENDANCE Certificate of Attendance with EACCME credits will be handed out from October 6 th (16:00) until the end of the congress. It will be necessary to fill in the CME Evaluation form before receiving the Certificate of Attendance. SATELLITE SYMPOSIUM Astra Zeneca Date: October 6 th, 2017 Time: 12:35 13:35 Venue: London I + II Agenda: Lunch symposium Role of SGLT-2 inhibitors in the treatment of diabetic patients 12:35 12:55 Patophysiology of cardiovascular and renal benefits of SGLT-2 inhibitors and its implications for clinical practice Speaker: Tkáč I (Slovakia) 12:55 13:35 SGLT-2 inhibitors and cardiovascular risk Speaker: Martinka E (Slovakia) INDUSTRY SPONSORED PRESENTATION Eli Lilly & Company Date: October 7 th Time: 11:40 12:00 Venue: London I + II Dulaglutide: a new once-weekly glucagon-like peptide-1 receptor agonist in clinical practice Speaker: Schroner Z (Slovakia)

19 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 19 Social Events WELCOME EVENING CRUISE ON DANUBE RIVER Date: Thursday, October 5th, 2017 Venue & Address: Boat Martin, Fajnorovo nábrežie 2, Staré Mesto, Bratislava Time: 19:30 22:30 Guided walk to the boat will start at 19:00 from the Reception of Crowne Plaza Hotel Important: boat capacity is limited to 150 persons, please register for the boat cruise at the congress registration desk at your earliest convenience. GALA DINNER Date: Friday, October 6th, 2017 Venue & Address: The Castle Restaurant (Reštaurácia Hrad), Námestie A. Dubčeka 1, Bratislava Time: 19:45 23:00 Admission: 49 Transportation will be provided. Meeting point: 19:30, Reception of Crowne Plaza Hotel Transfer to Crowne Plaza Hotel: 22:30 The Gala Dinner is not included in the registration fee. If you would like to attend the Gala Dinner, please check with the regi stration desk. Castle Restaurant offers a unique combination of traditional Slovak and international cuisine with elements of modern cuisine in an exceptional location directly below Bratislava Castle. Magnificent view of old Bratislava and delicious food prepared by highly professional staff offers its guests an unforgettable experience. MORNING EXCERCISE ACTIVITY Morning excersise will be performed in the garden of Grassalkovich (Presidential) Palace. Friday, October 6 th 7:00 7:30 Meeting Point: 06:50, Reception of Crowne Plaza Hotel Saturday, October 7 th 7:20 7:50 Meeting Point: 07:10, Reception of Crowne Plaza Hotel

20 20 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 Good to know LANGUAGE The official language of 6th Central European Congress on Obesity & 15th Slovak Congress on Obesity 2017 is English. Translation service will not be provided. TAXI Please use one of the recommended companies (operators speak English): Green Taxi ( for call and for sms), price approx. 5 Eur for 1 drive in the city, 8 Eur from the Airport Bratislava EASY TAXI ( for call), price approx. 5 eur for 1 drive in the city, 8 eur from the Airport Bratislava CURRENCY The official currency of the Slovakia Republic is Euro. International credit cards are accepted for payment in most hotels, restaurants and shops. Exchange offices and ATM machines are easily available throughout the city and at the Bratislava International Airport. You can find the official Exchange rates on the webiste of the Slovak National Bank. IMPORTANT TELEPHONE NUMBERS 112 Emergency calls 155 Ambulance, First Aid 158 Police 159 City Police 150 Fire Service 1181 Information about phone numbers (Slovakia) Information about phone numbers (international call) ELECTRICITY The Slovak Republic uses a 220 volt 50Hz system, sockets have the European standard and plugs are threeprong grounded. INSURANCE The organizers can accept no liability for personal injuries or for loss or damage to property belonging to the Congress participants, either during or as a result of the event. Participants are advised to take out proper travel and health insurance before departing from their home country.

21 6 th Central European Congress on Obesity and 15 th Slovak Congress on Obesity October 5 th 7 th, 2017, Bratislava, Slovakia SCHEDULE THURSDAY, October 5 th 2017 FRIDAY, October 6 th 2017 SATURDAY, October 7 th :00 7:30 Morning Exercise activity (place TBA) 7:20 7:50 Morning Exercise activity (place TBA) 7:30 19:00 Onsite Registration 7:30 16:00 Onsite Registration 8:00 9:20 Bariatric/Metabolic surgery I. 8:30 10:45 Management of obesity and its comorbidities chairs: Holéczy P (Slovakia), Wylezol M (Poland) chairs: Hainer V (Czech Republic), Tsigos C (Greece) 9:20 9:30 Coffee Break 9:30 11:20 Physical activity in the treatment of obesity, diabetes, and other comorbidities chairs: Holéczy P (Slovakia), Wylezol M (Poland) 9:20 9:30 Coffee Break 9:30 11:20 Physical activity in the treatment of obesity, 11:20 11:30 Vitamin Break diabetes, and other comorbidities chairs: Ukropcová B (Slovakia), Matoulek M (Czech Republic) 11:30 19:00 Onsite Registration 11:30 12:45 Co-morbidities of obesity chairs: Donič V (Slovakia), Staníková D (Germany/ Slovakia) 11:00 12:00 Obesity and type 2 diabetes chairs: Hainer V (Czech Republic), Tsigos C (Greece) 11:00 12:00 Obesity and type 2 diabetes chairs: Schroner Z (Slovakia), Haluzik M (Czech Republic) 12:00 12:45 Lunch Short Oral presentations (TOP 9 e-posters)# Guided poster session I # 12:45 13:45 13:00 13:30 Welcome Snack 12:45 13:45 Lunch symposium Guided poster session II # 13:30 14:30 Opening Ceremony 13:45 15:15 Childhood Obesity I. chairs: Kunešová M (Czech Republic), 14:30 15:00 Sečanský Inaugural Lecture Schusterová I (Slovakia) 15:00 15:20 Coffee Break 15:15 15:25 Coffee Break 14:45 15:00 Coffee break 15:20 16:50 Obesity epidemics Problem of Central Europe chairs: Toplak H (Austria), Fábryová Ľ (Slovakia), Halmy E (Hungary) 16:50 18:10 Do we need obesity specialists? round table discussion 15:25 16:55 Adipose tissue, thermogenic and metabolic organ chairs: Wolfrum C (Switzerland), Ukropec J (Slovakia) 13:45 14:15 Childhood Obesity II. chairs: Luger M (Austria), Hamar D (Slovakia) 16:55 17:10 Vitamin Break 16:30 16:45 Vitamin break 17:10 18:55 Genetics of Obesity and Diabetes chairs: Kovacs P (Germany), Gašperíková D (Slovakia) 19:00 23:00 Welcome evening 19:30 23:00 Gala Dinner at Restaurant Hrad (Bratislava Castle Restaurant) 15:00 16:30 Nutrition, Cognitive-Behavioral Therapy chairs: Kunešová M (Czech Republic), Kissová V (Slovakia), Slabá Š (Czech Republic) 16:45 17:40 Bariatric/Metabolic surgery II. chairs: Holéczy P (Slovakia), Gerauer KE (Germany) 17:50 18:00 Final remarks Last update on September 26 th, 2017

22 22 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 DETAILED PROGRAMME Thursday, October 5 th, :30 19:00 Onsite registration 13:00 13:30 Welcome snack 13:30 14:30 Opening and award ceremony Moderator: Holéczy P (Slovakia) Welcome address Ľubomíra Fábryová Chair of the Congress & President of the Obesitology Section of Slovakian Diabetes Society Andrej Kiska J. E. President of the Slovak Republic Tomáš Drucker Minister of Health of the Slovak Republic Hermann Toplak President of the European Association for the Study of Obesity Dana Müllerová Vice-President Middle Region of the European Association for the Study of Obesity Juraj Šteňo Dean of the Faculty of Medicine Comenius University in Bratislava Emil Martinka President of the Slovakian Diabetes Society 14:30 15:00 Sečanský inaugural lecture Monogenic diabetes and obesity in Slovakia Klimeš I, Staník J, Gašperíková D (Slovakia) A1 15:00 15:20 Coffee Break 15:20 16:30 Obesity epidemics Problem of Central Europe Chairs: Toplak H (Austria), Fábryová Ľ (Slovakia), Halmy E (Hungary) 15:20 15:45 Obesity in Europe Toplak H (Austria) A2 15:45 16:10 Situation in the management of obese patients in the Slovak Republic Fábryová Ľ (Slovakia) A3 16:10 16:30 Obesity management in Hungary. Hungarian comprehensive health tests program Halmy E, Kiss I, Daiki T, Dankovics G, Halmy L (Hungary) A4 16:30 16:50 Vitamin Break 16:50 18:10 Do we need obesity specialists? round table discussion Co-ordinator: Hainer V (Czech Republic) Participants: EASO Executive Committee: Toplak H (Austria), Yumuk V (Turkey), Müllerová D (Czech Republic) Representatives of the National Obesity Associations: Fried M (Czech Republic), Halmy E (Hungary), Olszanecka-Glinianowicz M (Poland), Fábryová Ľ (Slovakia), Holéczy P (Slovakia), Handjieva-Darlenska T (Bulgaria), Tsigos C (Greece) 19:00 23:00 Welcome evening (Cruise on the Danube River)

23 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 23 Friday, October 6 th :00 07:30 Morning Exercise Activity 07:30 19:00 Onsite Registration 08:00 09:20 Bariatric/Metabolic surgery I. Chairs: Holéczy P (Slovakia), Wylezol M (Poland) 08:00 08:20 Overview of new trends in bariatric and metabolic surgery Fried M (Czech Republic) A5 08:20 08:40 Predictors of weight loss and weight regain after obesity surgery Yumuk V (Turkey) A6 08:40 09:00 Surgery for diabetes and DSS-II guidelines Holéczy P (Slovakia) A7 09:00 09:20 Bariatric surgery in Poland. What s new? Wylezol M, Pasnik K (Poland) A8 09:20 09:30 Coffee Break 09:30 11:20 Physical activity in the treatment of obesity, diabetes, and other comorbidities Chairs: Ukropcová B (Slovakia), Matoulek M (Czech Republic) 09:30 09:50 Physical activity in the treatment of obesity or future is in the muscle Matoulek M (Czech Republic) A9 09:50 10:10 The effects and mediators of acute and regular exercise on glucose metabolism, cognitive and motor functions in middle-aged sedentary and elderly individuals Ukropcová B, Baláž M, Krumpolec P, Sobodová L, Tirpáková V, Janáková Z, Vajda M, Šutovský S, Cvečka J, Ukropec J (Slovakia) A10 10:10 10:30 High-Intensity Interval Training as a Therapy for Type 2 Diabetes? Pesta D (Gemany) A11 10:30 10:50 Does fat loss require fat burning? Role of exercised skeletal muscle Kuo C-H (Taiwan) A12 10:50 11:05 Effectiveness of complex non-pharmacological treatment of obese patients in Bardejov Spa Belovičová M, Matula P (Slovakia) A13 11:05 11:20 Prevention of type 2 diabetes through diet and physical activity: the PREVIEW study Handjieva-Darlenska T, Larsen TM, Westerterp-Plantenga M, Macdonald I, Martinez JA, Brand-Miller J, Poppitt S, Boyadjieva N, Handjiev S, Fogelholm M, Raben A (Bulgaria/ Denmark/Netherlands/UK/Spain/Australia/New Zealand/Finland/Denmark) A14 11:20 11:30 Vitamin Break 11:30 12:45 Co-morbidities of obesity Chairs: Donič V (Slovakia), Staníková D (Germany/Slovakia) 11:30 11:45 Obesity risk factor of cancer? Špánik S, Špániková B (Slovakia) A15 11:45 12:00 Obstructive sleep apnea and endocrinology Donič V, Doničová V (Slovakia) A16 12:00 12:15 Excessive daytime sleepiness in acute ischemic stroke; association with obesity, diabetes mellitus, restless legs syndrome and sleep-disordered breathing Šiarnik P, Kloubúčniková K, Szabó J, Mucska I, Kollar B, Turčani P (Slovakia) A17 12:15 12:30 Importance of different grades of abdominal obesity on testosterone level, erectile dysfunction, and clinical coincidence Fillo J, Levčíková M, Breza J, Mucska I (Slovakia) A18 12:30 12:45 Higher estrogen level is associated with depression in obese men Stanikova D, Luck T, Bae YJ, Thiery J, Ceglarek U, Engel C, Enzenbach C, Wirkner K, Kratzsch J, Riedel-Heller SG (Germany/Slovakia) A19 12:45 13:45 Lunch symposium: Role of SGLT-2 inhibitors in the treatment of diabetic patients 12:45 13:15 Patophysiology of cardiovascular and renal benefits of SGLT-2 inhibitors and its implications for clinical practice Tkáč I (Slovakia) A20 13:15 13:45 SGLT-2 inhibitors and cardiovascular risk Martinka E (Slovakia) A21

24 24 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity :45 15:15 Childhood obesity I. Chairs: Kunešová M (Czech Republic), Schusterová I (Slovakia) 13:45 14:00 Preventing childhood obesity in Hungary the GYERE program Szűcs Z, Kubányi J, Szigetvári S (Hungary) A22 14:00 14:15 Setting up obesity school programs: Challenges & examples Luger M (Austria) A23 14:15 14:30 Obesity reduction program School of obesity and utility of non-traditional risk factors and biomarkers in cardiovascular disease risk assessment Tóhátyová A, Schusterová I, Jarčušková M, Sadová E (Slovakia) A24 14:30 14:45 Risk factors of cardiovascular and metabolic diseases in Slovak adolescents: association with obesity Gerová Z, Janál D, Psota M, Štastná V (Slovakia) A25 14:45 15:00 Epicardial adipose tissue and cardiometabolic risk factors in overweight and obese children and adolescents Schusterová I, Tóhátyová A (Slovakia/Canada) A26 15:00 15:15 What is the influence of a weight loss program on cognitive functions in obese adolescents? Tresignie J, Vantieghem S, Bautmans I, Provyn S (Belgium) A27 15:15 15:25 Coffee Break 15:25 16:55 Adipose tissue, thermogenic and metabolic organ Chairs: Wolfrum C (Switzerland), Ukropec J (Slovakia) 15:25 15:45 Identification of the brown and brite adipocyte signature in mice and men Wolfrum C (Switzerland) A28 15:45 16:00 Metabolic and thermogenic activity of brown fat and obesity-related metabolic disease in men Ukropec J, Baláž M, Varga L, Krssak M, Štefanička P, Kiefer F, Wolfrum C, Ukropcová B (Slovakia) A29 16:00 16:15 Identification of novel targets with potential to promote brown adipocyte function Baláž M (Switzerland) A30 16:15 16:30 Dietary n-3 fatty acids as phospholipids improve insulin sensitivity of the liver and skeletal muscle in dietary obese mice Rossmeisl M, Pavlišová J, Kuchaříková P, Kalendová V, Kopecký J (Czech Republic) A31 16:30 16:45 Noninvasive MRI and MRS based approaches to study metabolism in obesity Chmelík M, Ukropec J, Gajdošík M, Valkovič L, Krssak M (Austria/Slovakia) A32 16:45 16:55 Treatment of osteoarthritis with freshly isolated stromal vascular fraction cells from adipose and connective tissue Michálek J, Dudášová Z (Czech Republic) A33 16:55 17:10 Vitamin Break 17:10 18:55 Genetics of obesity and diabetes Chairs: Kovacs P (Germany), Gašperíková D (Slovakia) 17:10 17:30 Pharmacogenomic aspects in the treatment of type 2 diabetes Tkáč I, Javorský M (Slovakia) A34 17:30 17:50 Genetics of obesity: Consequences for personalized medicine Kovacs P (Germany) A35 17:50 18:10 Development of adipose tissue in childhood obesity in children and relation to comorbidities Körner A (Germany) A36 18:10 18:25 A genome-wide association study using a custom genotyping array identifies variants in GPR158 associated with reduced energy expenditure and increased BMI and body adiposity in American Indians Mašindová I, Piaggi P (Slovakia/USA) A37 18:25 18:40 EIF2S3 mutations are associated with x-linked MEHMO syndrome Staník J, Škopková M, Henning F, Shin BS, Turner C, Kolníková M, Borck G, Gašperíková D, Dever T, Kalscheuer V (Germany/Slovakia) A38 18:40 18:55 Unweighted gene score as a BMI predictor in Czech males Hubáček JA, Dlouhá D, Lanská V, Adámková V (Czech Republic) A39 19:45 22:00 Gala Dinner at the Restaurant Hrad (Bratislava Castle Restaurant)

25 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 25 Saturday, October 7 th, :20 07:50 Morning Exercise Activity 07:30 16:00 Onsite Registration 08:30 10:45 Management of obesity and its comorbidities Chairs: Hainer V (Czech Republic), Tsigos C (Greece) 08:30 08:50 Clinical evaluation of the obese patient Tsigos C (Greece) A40 08:50 09:10 Very low energy diets: the past and presence Hainer V, Aldhoon-Hainerová I, Kunešová M, Zamrazilová H (Czech Republic) A41 09:10 09:30 The renaissance of obesity pharmacotherapy Olszanecka-Glinianowicz M (Poland) A42 09:30 09:45 Is obesity a real cardiovascular risk factor? Forster T, Nemes A (Hungary) A43 09:45 10:00 Management of arterial hypertension in obese patients Holecki M (Poland) A44 10:00 10:15 Mechanisms and potential targets of dyslipidaemia in obesity Fábryová L (Slovakia) A45 10:15 10:30 Non-alcoholic fatty liver disease in overweight and obese patients Skladaný L, Rác M, Szantová M, (Slovakia) A46 10:30 10:45 Obesity-related nephropathy Patasi A, Demeš M (Slovakia) A47 10:45 11:00 Coffee Break 11:00 12:00 Obesity and type 2 diabetes Chairs: Schroner Z (Slovakia), Haluzik M (Czech Republic) 11:00 11:20 Sarcopenic obesity: diagnosis and nutritional treatment Krajčík S, Mikuš P (Slovakia) A48 11:20 11:40 Targeting gastrointestinal tract in the treatment of obesity/type 2 diabetes Haluzík M (Czech Republic) A49 11:40 12:00 Dulaglutide: a new once-weekly glucagon-like peptide-1 receptor agonist in clinical practice Schroner Z (Slovakia) A50 12:00 12:45 Lunch 12:45 13:45 Short Oral presentations 12:45 13:45 Short Oral presentations London I + II Chairs: Ukropec J (Slovakia), Wolfrum C (Switzerland) 12:45 13:45 Guided e-poster session I. London III Chairs: Gašperíková D (Slovakia), Körner A (Germany) 12:45 13:45 Guided e-poster session II. Foyer Chairs: Ukropcová B (Slovakia), Pesta D (Gemany) 13:45 14:45 Childhood obesity II. Chairs: Luger M (Austria), Hamar D (Slovakia) 13:45 14:00 Childhood Obesity Surveillance Initiative (COSI) in the Czech Republic Kunešová M, Braunerová R, Zamrazilová H, Procházka B, Vignerová J, Pařízková J, Hill M, Šteflová A (Czech Republic) A51 14:00 14:15 Prevention of childhood obesity in Bulgaria Handjiev S, Handjieva-Darlenska T (Bulgaria) A52 14:15 14:30 Overweight and obesity in children WHO Childhood Obesity Surveillance Initiative in Slovakia Tichá Ľ, Regecová V, Sedláková D, Mesárošová I, Hamade J, Podracká L (Slovakia) A53 14:30 14:45 Whys and hows of physical exercise for children Hamar D (Slovakia) A54 14:45 15:00 Coffee Break

26 26 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity :00 16:30 Nutrition, Cognitive-Behavioral Therapy Chairs: Kunešová M (Czech Republic), Kissová V (Slovakia), Slabá Š (Czech Republic) 15:00 15:15 Fat: relation to obesity development and management Kunešová M (Czech Republic) A55 15:15 15:30 Fast versus slow weight loss: head to head comparison of effects on body composition and muscle strength in postmenopausal women with obesity the TEMPO diet trial Seimon RV, Gibson AA, Harper C, McClintock S, Hsu M SH, Fernando HA, Markovic TP, Franklin J, Center J, Liu PY, Byrne NM, Sainsbury A (Australia/United States) A56 15:30 15:45 Obesity and body image Herlesová J, Slabá Š (Czech Republic) A57 15:45 16:00 Internet as help in reducing weight and maintaining weight-loss Fraisová A, Málková I, Málková H (Czech Republic) A58 16:00 16:15 Cognitive Behavioral Treatment of obesity: Program STOB Majerčák I, Málková I (Slovakia/Czech Republic) A59 16:15 16:30 Motivation of obese patients for changes in behaviour Slabá Š (Czech Republic) A60 16:30 16:45 Vitamin Break 16:45 17:40 Bariatric/Metabolic surgery II. Chairs: Holéczy P (Slovakia), Gerauer KE (Germany) 16:45 17:00 Jejunoileal anastomosis novel procedure in bariatric/metabolic surgery technical aspect Holéczy P, Bolek M, Bužga M, Machytka E (Slovakia/Czech Republic) A61 17:00 17:15 Effect of endoscopic gastroplasty and surgical plication of the stomach on bodycomposition: short term, 6 months study Bužga M, Petreková K, Holéczy P, Machytka E (Czech Republic/Slovakia) A62 17:15 17:30 Guillain-Barré-syndrome following laparoscopic sleeve resection Gerauer KE, Grimm H, Leebman J, Motzek-Noé T (Germany) A63 17:30 17:40 Correlations between the distribution of ghrelin producing cells and anthropometric parameters in obese patients who underwent laparoscopic sleeve gastrectomy Mihalache L, Arhire LI, Padureanu SS, Ungureanu MC, Constantinescu R, Gherasim A, Nita O, Oprescu AC, Gavril RS, Danciu M (Romania) A64 17:40 17:50 Best short oral presentation and e-posters awards 17:50 18:00 Final remarks Last update on September 26 th, 2017

27 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 27 Short oral presentations (TOP 9 e-posters) (3 5 slides, 5-minute presentation + 1-minute discussion) Saturday, October 7 th, 2017, 12:45 13:45 London I + II Chairs: Ukropec J (Slovakia), Wolfrum C (Switzerland) Effects of a maternal Maillard reaction products-rich diet on offspring somatic and motoric development and metabolic status in a mice model Šebeková K, Somoza V, Gurecká R, Koborová I, Csongová M, Janšáková K, Celec P (Slovakia/Austria) A65 Functional state of muscle mitochondria in seniors with impaired glucose tolerance and mild cognitive impairment Nemec M, Maderová D, Krumpolec P, Slobodová L, Schön M, Sumbalová Z, Vician M, Ukropcová B, Ukropec J (Slovakia/Austria) A66 Nutrition management in bariatric metabolic surgery Danková M, Hašková A, Sadílková A, Matoulek M (Czech Republic) A67 Type 1 diabetes patients eating behaviour analysis alarming results Štechová K, Piťhová P, Kvapil M (Czech Republic) A68 Effect of chickpeas incorporation into Mankoushe on post prandial glycemia & lipidemia Dandashi S, Mawlawi H, Obeid O (Lebanon) A69 Screening for risk factors of NAFLD in Slovakia Szántová M, Skladaný L, Oltman M, Adamcová- Selčanová S, Janičko M, Rác M, Zima M, Belovičová M, Mészárosová Z, Dražilová S (Slovakia) A70 Stability and changes in feeding cues and quality of mealtime interaction: A longitudinal cross-cultural study of British and Israeli mothers and infants Shloim N, Rudolf M, Feltbower RG, Blundell-Birtill P, Hetherington MM (UK/Israel) A71 The effect of 8 weeks of weight loss intervention on cardiometabolic parameters (ongoing study) Penesová A, Bajer B, Vlček M, Imrich R (Slovakia) A72 Glucose metabolism, cognitive functions and physical (in)activity Schön M, Slobodová L, Tirpáková V, Krumpolec P, Vajda M, Vallová S, Valkovič P, Košutzká Z, Ukropec J, Ukropcová B (Slovakia) A73 Guided e-poster session I. (3-minute presentation + 1-minute discussion) Saturday, October 7 th, 2017, 12:45 13:45 London III Chairs: Gašperíková D (Slovakia), Körner A (Germany) The impact of obesity on alternative renin-angiotensin system pathways in adipose tissue Kršková K, Balážová L, Olszanecki R, Penesová A, Zorad Š (Slovakia/Poland) A74 Adipose tissue contributes to rapid normalization of macrophage and liver-cell lipid handling during dietary reversal of obesity, despite continued inflammation Vatarescu M, Bechor S, Haim Y, Pecht T, Tarnovsky T, Bashan N, Rudich A (Israel) A75 Hydrogen-rich water alleviates ethanol induced fatty liver via anti-oxidation and anti-inflammation in mice Chen CY, Lin CP (Taiwan) A76 Obesity brings forward the age-related changes of food intake regulation by anorexigenic neuropeptides in rats Székely M, Pétervári E, Balaskó M (Hungary) A77 Extracellular DNA and bariatric surgery Celec P, Čierny M, Konečná B, Vlková B (Slovakia/Czech Republic) A78 Management of a chronic staple line leak following laparoscopic sleeve resection Gerauer KE, Grimm H (Germany) A79 Are proton pump inhibitors associated with weight gain? Huang HH, Chen CY (Taiwan) A80 Non-invasive determination of liver fibrosis in patients with non-alcoholic fatty liver and cardiometabolic risk factors Szántová M, Ostrochovská S, Hlavatá T, Ďurkovičová Z, Holomáň J, Glasa J, Luha J (Slovakia) A81

28 28 6 th Central European Congress on Obesity (CECON) and 15 th Slovak Congress on Obesity 2017 Fatty liver screening based on fatty liver index (FLI) Hlavatá T, Szántová M, Luha J, Melicháčová V, Kabátová J, Bačíková Z, Nedelková Z, Graňo F (Slovakia) A82 Metabolic factors and non-alcoholic fatty liver in patients with impaired glucose tolerance Sianni A, Matsoukis IL, Ganotopoulou A, Triantafillopoulou C, Kanellopoulou K, Skorda L (Greece) A83 Prevalence and risks factors of new-onset diabetes mellitus after liver transplantation (NODAT): singlecentre experience Skladaný L, Mésárosová Z, Dedinská I, Adamcová-Selčanová S (Slovakia) A84 Overweight, obesity, and putative contribution of non-alcoholic fatty liver disease (NAFLD) to the patients undergoing liver transplantation (LTx) for etiologies other than NAFLD: analysis of the cohort Skladaný L, Badinková J, Bachová B, Adamcová-Selčanová S (Slovakia) A85 Obesity and posttransplant diabetes mellitus in Slovakia Dedinská I, Laca Ľ, Miklušica J, Galajda P, Mokáň M (Slovakia) A86 Guided e-poster session II. (3-minute presentation + 1-minute discussion) Saturday, October 7 th, 2017, 12:45 13:45 Foyer Chairs: Ukropcová B (Slovakia), Pesta D (Gemany) Pigment epithelium derived factor and C1q/TNF-related protein 9 in patients with type 2 diabetes; their relationship to metabolic syndrome and vascular damage Karásek D, Gajdová J, Kubíčková V, Krystyník O, Cibičková L (Czech Republic) A87 Effect of aging on lipogenic potential of human subcutaneous adipose tissue and adipocytes Rossmeislová L, Šrámková V, Koc M, Šiklová M, Krauzová E, Langin D, Štich V (Czech Republic/France) A88 Obesity and T2DM related changes of skeletal muscle secretory profile: in vitro and in vivo studies Máderová D, Kurdiová T, Baláž M, Vician M, Gašperíková D, Belan V, Ukropcová B, Ukropec J (Slovakia) A89 Diurnal changes of acetylcarnitine in human vastus lateralis muscle and response to exercise Klepochová R, Valkovič L, Gajdošík M, Krssak M (Austria/UK) A90 Concordance of bioactive vs. total immunoreactive serum leptin levels in children and adolescents with severe early onset obesity Staník J, Kratzsch J, Landgraf K, Schuermann K, Spielau U, Gausche R, Gašperíková D, Kiess W, Körner A (Slovakia/Germany) A91 Contribution of GP to prevention of stroke in atrial fibrillation, how obesity can be dangerous Macháčová M, Murín J, Bendová J (Slovakia) A92 How many risk factors affecting body weight reduction we know? Buková L, Galajda P, Mokáň M (Slovakia) A93 The effect of the regulation on the trans fatty acid content of foods Varga A, Bakacs M, Illés E, Kaposvári C, Nagy B, Cserháti Z (Hungary) A94 Assessment of nutritional state of professional soldiers in the Armed Forces of the Czech Republic in view of new regulation about evaluating the health capability of active-duty service Fajfrová J, Pavlík V, Šafka V (Czech Republic) A95 Three months aerobic-strength training and nutritional preference in relation with functional status, metabolism and cognitive functions in seniors with Mild Cognitive Impairment Slobodová L, Tirpáková V, Krumpolec P, Vajda M, Vallová S, Cvečka J, Šutovský S, Turčáni P, Sedliak M, Ukropec J, Ukropcová B (Slovakia) A96 STOB activities aimed at weight reduction and weight maintenance with regard on degree of patients readiness Málková I, Málková H (Czech Republic) A97 The effect of mexiletine on body weight in type 2 diabetes patients with visceral obesity Ueno N (Japan) A98 Self-perceived fatigue and physical performance in Flemish school children Provyn S, Vantieghem S, Bautmans I, Tresignie J (Belgium) A99

29 October 5 th October 7 th, Crowne Plaza Hotel, Bratislava, Slovakia 29 Unmoderated (displayed) e-poster presentations The different effect of angiotensin 1 7 receptor agonist (AVE 0991) administration on the local reninangiotensin system of metabolically active tissues in obese Zucker rats Lóry V, Slamková M, Kršková K, Balážová L, Suski M, Olszanecki R, Zorad S (Slovakia/Poland) A100 The effect of high-energy diet on Zucker diabetic fatty rats Capcarová M, Schwarzová M, Kalafová A, Lóry V, Šoltésová Prnová M, Švík K, Schneidgenová M, Zorad S (Slovakia) A101 Administration of peroxisome proliferator-activator receptor alpha (PPAR-alpha) agonist reduces body weight and adipose depots in fructose fed Wistar rats Atanasovska E, Pavlovska K, Jakjovski K, Gjorgjievska K, Zendelovska D, Petrushevska M, Labachevski N (Macedonia) A102 Feeding and metabolism altering attributes of the glucose-monitoring neurons in the cingulate cortex of the rat Hormay E, Csetényi B, Szabó I, Karádi Z (Hungary) A103 Metabolic alterations after interleukin-1β microinjection into the cingulate cortex of the rat Csetényi B, Hormay E, Szabó I, Karádi Z (Hungary) A104 The use of newly discovered myokine irisin as a biomarker for individualised recommendation for physical exercise in obese individuals Arhire LI, Nita O, Gherasim A, Oprescu AC, Mitu O, Roca M, Leustean L, Gavril RS, Gavril I, Mihalache L (Romania) A105 Association between biomarkers of adipose-tissue inflammation and immune response: A metaanalysis Aleksandrova K, Graßmann S, Wirsching J, Eichelmann F (Germany) A106 Assessment of the resting energy expenditure in obese individuals Sadílková A, Matoulek M, Hásková A, Daňková M (Czech Republic) A107 Linking adaptive response to regular exercise in muscle and brain Jacková L, Janáková Z, Slobodová L, Valkovič P, Tirpáková V, Krumpolec P, Turčáni P, Sedliak M, Ukropcová B, Ukropec J (Slovakia) A108 Fat makes adolescents feel tired Vantieghem S, Tresignie J, Bautmans I, Provyn S (Belgium) A109 Super obesity and bariatric surgery is the gastric balloon always useful? Gerauer KE, Grimm H, Maaßen S, Leebmann J (Germany) A110 Gastric perforation, a rare complication of gastric balloon (Case report) El-Kurdi MAR (Egypt) A111 Food habits and nutritional status in Hungarian young people Uvacsek M, Németh A (Hungary) A112 Evaluation of nutrition-related risk factors among the Hungarian adult population Nagy B, Bakacs M, Nagy-Lőrincz Z, Nagy E, Illés E (Hungary) A113 Which foods are deficient in the diet of patients with type 2 diabetes? Buková L, Galajda P, Mokáň M (Slovakia) A114 The dietary habits of the Hungarian adult population Hungarian diet and nutritional status survey (OTÁP2014) Nagy-Lőrincz Z, Nagy B, Bakacs M, Illés E (Hungary) A115 Investigation on the existence of eating disorders and differences to eating habits, in students aged years old in the city of Nafpaktos, in resting conditions and in exams period Milona AD, Karaoulanis S, Tsiouri I, Bonotis K (Greece) A116 Association between lipoprotein(a) and fatty liver disease in non-alcoholic patients Sianni A, Matsoukis IL, Ganotopoulou A, Triantafillopoulou C, Kanellopoulou K, Skorda L (Greece) A117 Half-century trends of obesity development in Slovak population dietetic possibilities of obesity correction and its complications Kajaba I, Hrušovský Š, Babjaková J, Fábryová L, Belovičová M, Krahulec B, Staruch L (Slovakia) A118 Consumer perspectives about weight management services in a community pharmacy setting in Albania Pistja E, Themeli A (Albania) A119 Effectiveness of cognitive behavioral therapy on changes of anthropometric and biochemical parameters in group weight reduction courses Vymlátilová L, Fajfrová J, Pavlík V (Czech Republic) A120 Determination of slimming effect by auricular acupuncture stimulation statistical analysis of 1017 female data Fujimoto T, Masuda H, Hataoka T, Kobayashi H (Japan) A121 Last update on September 26 th, 2017

30 POZNÁMKY

31

32